Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer

BACKGROUND: Enzalutamide is an androgen receptor (AR) inhibitor that acts on different steps in the AR signaling pathway. In PREVAIL, an international, phase III, double-blind, placebo-controlled trial, enzalutamide significantly reduced the risk of radiographic progression by 81% (hazard ratio [HR]...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: Kim, Choung Soo, Choi, Young Deuk, Lee, Sang Eun, Lee, Hyun Moo, Ueda, Takeshi, Yonese, Junji, Fukagai, Takashi, Chiong, Edmund, Lau, Weber, Abhyankar, Sarang, Theeuwes, Ad, Tombal, Bertrand, Beer, Tomasz M., Kimura, Go
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2017
Assuntos:
7300
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5502144/
https://ncbi.nlm.nih.gov/pubmed/28682871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000007223
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados